Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 1.00 |
| ▸ | CDK4 | P11802 | 6/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 5/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470162 | 0.86 | CDK2 (1.00) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL411464 | 0.86 | CDK2 (0.75) | CDK2CDK4CCNE1HDAC1KDM4E | |
| SCHEMBL1684670 | 0.82 | CDK2 (0.76) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL1684693 | 0.80 | CDK2 (0.80) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL1684643 | 0.79 | CDK2 (0.86) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL7978525 | 0.79 | CDK2 (0.73) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL699562 | 0.79 | CDK2 (0.73) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL7964840 | 0.78 | CDK2 (1.00) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL21208238 | 0.78 | CDK2 (0.74) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL7974684 | 0.78 | CDK2 (0.66) | CDK2CDK4CCNE1HDAC1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4256086-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2022119842-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20070099938-A1 | Antistress drug and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1679309-A1 | ANTISTRESS DRUG AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099938-A1 | Antistress drug and medical use thereof | NPSR1, MC2R, SRR | CDK2 3499/4885CDK4 3460/4885CCNE1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.